Immunogenicity of COVID-19 Vaccines in Patients with Diverse Health Conditions: a Comprehensive Systematic Review.
Por:
Cho K, Park S, Kim EY, Koyanagi A, Jacob L., Yon DK, Lee SW, Kim MS, Radua J, Elena D, Il Shin J and Smith L
Publicada:
1 sep 2022
Ahead of Print:
13 may 2022
Resumen:
It remains unclear how effective COVID-19 vaccinations will be in patients with weakened immunity due to diseases, transplantation, and dialysis. We conducted a systematic review comparing the efficacy of COVID-19 vaccination in patients with solid tumor, hematologic malignancy, autoimmune disease, inflammatory bowel disease, and patients who received transplantation or dialysis. A literature search was conducted twice using the Medline/PubMed database. As a result, 21 papers were included in the review, and seropositivity rate was summarized by specific type of disease, transplantation, and dialysis. When different papers studied the same type of patient group, a study with a higher number of participants was selected. Most of the solid tumor patients showed a seropositivity rate of more than 80% after the second inoculation, but a low seropositivity was found in certain tumors such as breast cancer. Research in patients with certain types of hematological malignancy and autoimmune diseases has also reported low seropositivity, and this may have been affected by the immunosuppressive treatment these patients receive. Research in patients receiving dialysis or transplantation has reported lower seropositivity rates than the general population, while all patients with inflammatory bowel disease have converted to be seropositive. Meta-analysis validating these results will be needed, and studies will also be needed on methods to protect patients with reduced immunity from COVID-19. This article is protected by copyright. All rights reserved.
Filiaciones:
Cho K:
Yonsei University, College of Medicine, Seoul, Republic of Korea
Park S:
Yonsei University, College of Medicine, Seoul, Republic of Korea
Kim EY:
Evidence-Based and Clinical Research Laboratory, Department of Health, Social and Clinical Pharmacy, College of Pharmacy, Chung-Ang University, Seoul, 06974, Korea
Koyanagi A:
ICREA, Pg. Lluís Companys 23, 08010, Barcelona, Spain
Research and Development Unit, Parc Sanitari Sant Joan de Déu, CIBERSAM, 08830, Barcelona, Spain
Jacob L.:
Research and Development Unit, Parc Sanitari Sant Joan de Déu, CIBERSAM, 08830, Barcelona, Spain
Faculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines, 78180, Montigny-le-Bretonneux, France
Yon DK:
Department of Pediatrics, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea
Lee SW:
Department of Data Science, Sejong University College of Software Convergence, Seoul, Republic of Korea
Kim MS:
Samsung Advanced Institute for Health Sciences and Technology (SAIHST), Sungkyunkwan University, Samsung Medical Center, Seoul, Republic of Korea
Radua J:
Early Psychosis: Interventions and Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, SE5 8AB, UK
Mental Health Networking Biomedical Research Centre (CIBERSAM), 08036, Barcelona, Spain
Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institute, 11330, Stockholm, Sweden
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036, Barcelona, Spain
Elena D:
Pain and Rehabilitation Centre, and Department of Health, Medicine and Caring Sciences, Linköping University, SE-581 85 Linköping, Sweden
Il Shin J:
Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea
Smith L:
Centre for Health, Performance and Wellbeing, Anglia Ruskin University, Cambridge, UK
Green Accepted, Green Published
|